A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A phase 2 trial of F182112, Pomalidomide in multiple myeloma, run by Shandong New Time Pharmaceutical Co., LTD, now recruiting.
Overview
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07312188 by Shandong New Time Pharmaceutical Co., LTD, with 90 participants planned, started 2025-07-02 and due to reach its primary completion in 2028-05-20. Interventions recorded: F182112+P, F182112+CD38. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shares F182112, Shandong New Time Pharmaceutical, Multiple myeloma.
- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Pomalidomide, Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Multiple myeloma.
- TrialAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Pomalidomide, Multiple myeloma.
- TrialA Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme
Shares Pomalidomide, Multiple myeloma.
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Multiple myeloma.
- TargetCereblon (CRBN)
Shares Pomalidomide, Multiple myeloma.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Multiple myeloma.